Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Clinical trial NCT02999854 · TERMINATED
Trial details
- NCT number
- NCT02999854
- Sponsor
- Kiadis Pharma
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-29
- Primary completion
- 2021-11-09
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.